Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30024568 | 0.89 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTL3MBTL1KDM4E | |
| SCHEMBL5387829 | 0.89 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTL3MBTL1KDM4E | |
| SCHEMBL17153223 | 0.87 | SIGMAR1 (0.58) | SIGMAR1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL4573720 | 0.86 | KCNJ1 (0.65) | SIGMAR1ALDH1A1LMNAMAPTKCNJ1 | |
| SCHEMBL402564 | 0.84 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL21643470 | 0.83 | MAPT (0.52) | SIGMAR1ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL29803029 | 0.83 | MAPT (0.52) | SIGMAR1ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL4717096 | 0.83 | SIGMAR1 (0.71) | SIGMAR1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL27703661 | 0.83 | SIGMAR1 (0.58) | SIGMAR1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL17554422 | 0.83 | ALDH1A1 (0.54) | SIGMAR1ALDH1A1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264133-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2025-04-01 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-10385023-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | disclosed |
| US-10035770-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2862859-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2017-09-21 | — | — | US | disclosed |
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007070626-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | SIGMAR1 3079/4885ALDH1A1 3619/4885LMNA 410/4885 |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | SIGMAR1 3322/4885ALDH1A1 4250/4885LMNA 681/4885 |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-10385023-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-12264133-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-20070197497-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-10975034-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-10035770-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | SIGMAR1 3801/4885ALDH1A1 4381/4885LMNA 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.